1. Introduction
Hops (
Humulus lupulus L., Cannabaceae) have long been valued not only as a key ingredient in the brewing industry but also as a source of biologically active secondary metabolites. Among the prenylflavonoids isolated from the female inflorescences of hops, xanthohumol (XN,
Figure 1)—a prenylated chalcone—has emerged as one of the most pharmacologically promising compounds [
1]. Over the last two decades, XN has been reported to display a remarkably broad spectrum of bioactivities, including antioxidant, anti-inflammatory, antimicrobial, antiviral, hepatoprotective, antidiabetic, cardioprotective, and chemopreventive effects [
2]. Its anticancer activity has attracted particular attention, with studies demonstrating apoptosis induction, inhibition of angiogenesis, modulation of NF-κB and Wnt/β-catenin signalling, and suppression of cytochrome P450-mediated procarcinogen activation across a variety of tumour cell lines [
3,
4].
Despite this attractive pharmacological profile, the translation of XN into clinically or nutraceutically relevant formulations is limited by its unfavourable physicochemical properties. XN is a highly lipophilic molecule (logP ≈ 4.5, where logP is the logarithm of the n-octanol/water partition coefficient) with low aqueous solubility (<1 µg/mL), poor oral bioavailability, and substantial chemical instability—undergoing rapid intramolecular cyclisation to its less active flavanone isomer, isoxanthohumol, under acidic, thermal, or light-exposed conditions [
5,
6]. These limitations impose significant constraints on the in vivo plasma concentrations, thereby impeding the development of effective dosage forms. Consequently, considerable effort has been directed towards the design of advanced delivery systems capable of enhancing the solubility, stability, and bioavailability of XN, including cyclodextrin inclusion complexes, micelles, solid lipid nanoparticles, polymeric nanoparticles, and lipid-based vesicular carriers [
7,
8].
Among these strategies, liposomes—spherical vesicles composed of one or more phospholipid bilayers enclosing an aqueous core—represent one of the most extensively investigated and clinically validated nanocarriers [
9]. Their structural similarity to biological membranes endows them with excellent biocompatibility and biodegradability, while their amphiphilic architecture enables the simultaneous encapsulation of hydrophilic compounds within the inner aqueous compartment and of lipophilic compounds, such as XN, within the phospholipid bilayer [
10]. Liposomal encapsulation has been shown to protect XN from oxidative and photochemical degradation, increase its water solubility, and improve its cellular uptake [
11]. Nevertheless, conventional liposomes still suffer from several well-documented drawbacks, including physical instability during storage (aggregation, fusion, and phospholipid hydrolysis), drug leakage, burst release, susceptibility to bile salts and digestive enzymes in the gastrointestinal tract, and rapid clearance by the mononuclear phagocyte system following systemic administration [
12]. These limitations have motivated extensive research into surface engineering of liposomes to improve their robustness and modulate their biological fate.
Coating liposomes with biocompatible polysaccharides has emerged as a particularly attractive surface-modification strategy. Natural polysaccharides such as chitosan, alginate, pectin, hyaluronic acid, carboxymethyl cellulose, and various gums are inexpensive, non-toxic, biodegradable materials and bear functional groups (–OH, –NH
2, –COOH) that allow versatile chemical and physical modification [
13]. Adsorption of polyelectrolyte chains onto the liposomal surface—typically driven by electrostatic and hydrogen-bonding interactions—produces a hydrated polymeric corona that sterically and/or electrostatically stabilises the vesicles, suppresses phospholipid oxidation, hinders premature drug leakage, and confers mucoadhesive properties beneficial for oral, buccal, nasal, and ocular delivery [
14,
15]. Polysaccharide coatings can additionally provide pH- and enzyme-responsive behaviour, enabling site-specific release in the gastrointestinal tract or in the tumour microenvironment [
16,
17].
The performance of polysaccharide-coated liposomes can be further reinforced through chemical or ionic cross-linking of the surface polymer layer [
18,
19]. Cross-linking—for example, ionotropic gelation of alginate or pectin with Ca
2+, electrostatic cross-linking of chitosan with sodium tripolyphosphate, or covalent cross-linking with naturally derived agents such as genipin—converts the loosely adsorbed polymer corona into a denser, network-like shell [
19,
20]. This dense shell can improve vesicle integrity against mechanical stress, dilution, freeze-drying, and gastrointestinal fluids, while simultaneously enabling sustained and more controllable release kinetics of the encapsulated drug load [
18,
21]. Cross-linked polysaccharide-coated liposomes thus combine the encapsulation versatility of liposomes with the mechanical and biological resilience of hydrogel-like polymeric shells, representing a particularly suitable platform for the delivery of lipophilic molecules sensitive to stability, such as XN.
Despite the clear rationale, reports describing the encapsulation of XN into cross-linked polysaccharide-coated liposomes remain limited, and a systematic understanding of how the coating composition and cross-linking conditions influence the physicochemical stability and release performance of XN-loaded vesicles is still lacking. Thus, the aim of the present study was to develop and characterize XN-loaded liposomes coated with iota-carrageenan and fucoidan and subsequently cross-linked with CaCl2, and to evaluate the resulting nanocarriers in terms of particle size, zeta potential, polydispersity index, encapsulation efficiency, in vitro release behaviour, and test whether the constructed shell will successfully provide a shield against macrophage uptake, giving potential “stealth-like” properties of the formulated vesicles.
2. Materials and Methods
2.1. Chemicals and Reagents
Xanthohumol (Mw 354.39 g/mol) was purchased from Cayman Chemicals (Ann Arbor, MI, USA), LIPOID PC 16:0/16:0 (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine, DPPC), and LIPOID DOTAP-Cl (1,2-Dioleoyloxy-3-trimethylammonium-propane chloride, DOTAP) were purchased from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol (from sheep wool, ≥92.5%), Fucoidan (from Fucus vesiculosus ≥ 95%), Carrageenan (iota-type), CaCl2 (Mw: 110.98 g/mol, ≥97.0%), FITC (Fluorescein 5(6)-isothiocyanate, Mw 389.38) and DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Trisodium citrate was purchased from Fillab (Plovdiv, Bulgaria). Ethanol (99.9%) was purchased from RaiChim (Plovdiv, Bulgaria), and acetonitrile and methanol (analytical grade) were purchased from Merck KGaA (Darmstadt, Germany).
2.2. Preparation of Xanthohumol-Loaded Liposomes
Xanthohumol-loaded liposomes were prepared by the ethanol injection method, described previously [
22]. Briefly, DPPC, DOTAP, cholesterol, and Xanthohumol were dissolved in 10 mL of absolute ethanol. The resulting solution was heated above the phase transition temperature of the lipids (45 °C) and injected rapidly through 27G needle into 100 mL of ultrapure water, which was also heated to the same temperature. The suspension was kept under magnetic stirring for a period of 1 h, and then the residual ethanol was evaporated using the BUCHI RII Rotavapor rotary vacuum evaporator (BÜCHI Labortechnik AG, Flawil, Switzerland) under reduced pressure. After that, the liposomal suspension was stored at 4 °C overnight to allow complete vesicle formation. Nine models were prepared with varying lipid concentration, DPPC: DOTAP: Cholesterol ratio, and Lipid phase: Xanthohumol ratio using 2
3 + 1 full factorial experimental matrix. All preparations were performed as three independent batches to ensure reproducibility.
2.3. Surface Modification of the Liposomes
The formulated xanthohumol-loaded liposomes were further modified by the method of single-layer deposition with subsequent cross-linking of the formed coating with CaCl
2 [
23]. Two anionic marine polysaccharides were selected, namely iota-carrageenan and fucoidan. The optimal polysaccharide-to-liposome ratio for single-layer deposition was determined by polyelectrolyte titration based on ζ-potential measurements. A series of mixtures was prepared at different polysaccharide-to-liposome weight ratios (
w/
w): (1:15, 1:10, 1:5, 1:3, 1:1, 3:1, 5:1, 10:1, 15:1). For each ratio, the defined volume of liposomes with a concentration of 1.0 mg/mL was added dropwise to a solution of polysaccharide with a concentration of 1.0 mg/mL under continuous magnetic stirring. The mixtures were incubated for 60 min at room temperature. The ζ-potential of each mixture was measured, and the optimal ratio for each polysaccharide was defined as the point at which electrostatic saturation of the liposomal surface was reached (i.e., the ratio beyond which no further significant change in ζ-potential occurred).
After defining the optimal polysaccharide-to-liposome ratios, the liposomes were coated with a single layer of the corresponding polysaccharide. Nine models were prepared using an L9 Taguchi orthogonal array. A defined amount of liposomes at concentration of 1 mg/mL was added dropwise to a solution of polysaccharide with varying concentrations (0.5 mg/mL, 1.0 mg/mL, 2.0 mg/mL) at a fixed polysaccharide: liposomes ratio. The suspension was incubated for 30 min, 60 min, or 120 min. Subsequently, a solution of CaCl2 was added at varying concentrations (1 mM, 5 mM, 10 mM), and the suspension was kept stirring for another 60 min to achieve complete equilibrium.
2.4. Liposomes Particle Average Size, Particle Size Distribution and ζ-Potential
The average particle diameter, particle size distribution, and ζ-potential of the formulated liposomes as well as the surface-modified liposomes were determined via dynamic and electrophoretic light scattering with a particle size analyser (Zetasizer UltraRed, Malvern Panalytical Ltd., Malvern, UK).
2.5. HPLC-PDA Quantitative Analysis of Xanthohumol
2.5.1. Preparation of Standard and Test Solutions and Chromatographic Conditions
The standard compound XN was prepared as a stock solution at a concentration of 1 mg/mL using an acetonitrile/water mixture (50:50, v/v). To enhance dissolution, the solution was treated in an ultrasonic bath (Bandelin, Berlin, Germany). Subsequently, working standard solutions were obtained by serial dilution with the same acetonitrile/water mixture to cover the required validation range. Test samples were similarly diluted with acetonitrile/water (50:50, v/v) to fall within the validated concentration range. The method was established using an LC40-PDA system (Shimadzu, Kyoto, Japan) fitted with a Shim-pack C18 column (150 mm × 4.6 mm, 3 μm, Shimadzu, Kyoto, Japan). Isocratic elution was applied to improve separation efficiency. The mobile phase consisted of water (A), methanol (B), and acetonitrile (C), with an overall composition of 25% A, 10% B, and 65% C. The flow rate was maintained at 0.6 mL/min, and the column temperature was set to 40 °C. A sample volume of 10 μL was injected for analysis. UV–Vis spectra were recorded over the range of 190–800 nm, while chromatographic detection was performed at 370 nm. Data acquisition and processing were carried out using LabSolutions software (version 5.118, Shimadzu, Kyoto, Japan). All test samples for entrapment efficiency and in vitro release determination were diluted as required so that their xanthohumol concentrations fell within the validated calibration range.
2.5.2. Validation of the HPLC-PDA Method
The developed method was validated in accordance with the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (EMA ICH Q2(R2) Validation of Analytical Procedures—Scientific Guideline) [
24]. For Linearity, quantitative analysis was performed using the external standard method. Calibration standards were prepared at six concentration levels within the range of 5–75 µg/mL and analyzed in triplicate to establish calibration curves. The linearity of the method was evaluated by plotting the peak area versus the nominal concentration of the standards. The coefficient of determination (R
2) was calculated as an indicator of linearity. The parameters Limit of detection (LD) and quantification (LQ) were calculated based on the linearity data, using the standard deviation of the response and the slope of the calibration curve. The accuracy of the proposed method was assessed by determining the percentage recovery. Three quality control levels were examined for each analyte: low (10 µg/mL), medium (30 µg/mL), and high (50 µg/mL). The recovery results demonstrated that the method provides satisfactory accuracy across the investigated concentration range. Method precision was evaluated in terms of both intra-day and inter-day repeatability. Intra-day precision was determined by analyzing freshly prepared samples at the three quality control levels, each in six replicates within a single day. Inter-day precision was assessed by analyzing freshly prepared samples at the same concentration levels over three consecutive days, with six replicates per level. The parameter robustness was evaluated by examining the effect of variations in column temperature on chromatographic performance. The column temperature was deliberately varied between 38 °C and 42 °C, and the retention times of the analytes were monitored. No significant changes in resolution were observed, indicating that small temperature fluctuations did not adversely affect the chromatographic separation, thereby confirming the robustness of the method. In addition, the influence of the flow rate was also investigated by applying a variation of ±2% from the nominal value. These minor changes did not produce any significant effect on the chromatographic performance, further demonstrating the stability and reliability of the developed method.
The results for linearity, as well as the calculated limits of detection and quantification, are summarized in
Table S1, whereas the outcomes of the accuracy and precision assessments are presented in
Tables S2 and S3, respectively, presented as
Supplementary Materials.
2.6. Entrapment Efficiency of Xanthohumol (EE)
The EE was determined for the unmodified liposomes as well as the modified models by measurement of the incorporated xanthohumol. Unentrapped xanthohumol was separated by ultracentrifugation [
25]. An aliquot of each formulation was centrifuged at 30,070×
g for 90 min at 4 °C using a Sigma 3-18KS centrifuge equipped with a fixed-angle rotor (Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany). The pellet containing the vesicles was incubated with methanol and sonicated for 10 min to ensure complete lysis of the vesicles and complete solubilization of xanthohumol. For the surface-modified liposomes, the same procedure was applied, but prior to incubation with methanol, 50 mM trisodium citrate was added to chelate Ca
2+ and incubated for 30 min, in order to dissolve the coating shell. Then, the liposomes were subjected to ultracentrifugation at the aforementioned conditions, and then the pellet was incubated with methanol to solubilize the xanthohumol. The EE was calculated according to the following Equation (1):
where:
Wentrapped—amount of incorporated Xanthohumol
Wtotal—total amount of Xanthohumol
For surface-modified liposomes, Wtotal was taken as the mass of xanthohumol entrapped in the optimal uncoated formulation prior to the coating step.
2.7. In Vitro Drug Release Study
The in vitro release of xanthohumol from the formulated uncoated and coated liposome models was evaluated using the dialysis bag method. The release medium consisted of phosphate-buffered saline (PBS, pH 7.4) supplemented with 20% (
v/
v) methanol to enhance solubilization of the poorly water-soluble xanthohumol [
3,
26,
27]. The release medium was freshly prepared on the day of the experiment and equilibrated at 37 ± 0.5 °C prior to use. An aliquot of each formulation was placed inside a pre-soaked, 12 kDa MWCO dialysis membrane (Sigma, MWCO 12 kDa), which was hydrated in ultra-pure water overnight and sealed with a plastic clamp. Each bag was then immersed in a beaker containing 200 mL of release medium and maintained under constant gentle agitation on an electromagnetic stirrer at 150 rpm and 37.0 ± 0.5 °C. Aliquots of 2 mL were withdrawn at set intervals and replaced with fresh medium. The amount of released xanthohumol was determined by the method described in
Section 2.5.
To confirm that the dialysis membrane did not retain xanthohumol and bias the measured release, a control experiment was performed in which 10 mL of free (non-encapsulated) xanthohumol solution, prepared in the release medium, was placed in the dialysis bag and dialysed against 200 mL of the same medium under conditions identical to the release experiments. After 1 h, approximately 97% of the xanthohumol was recovered in the acceptor compartment, and approximately 2.8% remained in the donor compartment, giving a mass balance of ~99.8%. The near-complete recovery confirms that the membrane was freely permeable to xanthohumol and did not significantly adsorb or retain the drug.
2.8. In Vitro Macrophage Uptake Assay
2.8.1. Preparation of FITC-Labelled Liposomes
For cellular uptake studies, fluorescently labelled liposomes were prepared with the same lipid composition, coating, and cross-linking as the xanthohumol-loaded formulations, with fluorescein isothiocyanate (FITC) encapsulated within the aqueous core as a fluorescent tracer. FITC was added to the aqueous hydration phase at an initial concentration of 0.1 mg/mL. The liposomes were formed by the ethanol injection method (
Section 2.2) and coated and cross-linked as described (
Section 2.3). Unencapsulated free FITC was removed prior to all cellular experiments by ultracentrifugation under the same conditions used for the xanthohumol-loaded formulations (30,070×
g for 90 min at 4 °C), and the amount of FITC incorporated was determined subsequently to be 0.052 mg/mL, corresponding to an encapsulation efficiency of approximately 52%. These FITC-labelled liposomes, matched in composition and surface modification to the drug-loaded formulations, were used to assess cellular uptake.
2.8.2. Cell Lines and Culture Conditions
The following cell lines were used in the experiments: A549 (ATCC CCL-185™)—human lung adenocarcinoma cells, HFFC—human foreskin fibroblasts (CLS Cell Lines Service GmbH, Eppelheim, Germany), RAW264.7 (ATCC TIB-71)—a mouse macrophage cell line established from a tumor induced by the Abelson leukemia virus. The carcinoma cell line and RAW264.7 macrophages were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Merck KGaA, Darmstadt, Germany), supplemented with 10% fetal bovine serum (FBS) (Merck KGaA, Darmstadt, Germany) and a mixture of antibiotics (100 µg/mL streptomycin and 100 IU penicillin /Merck KGaA, Darmstadt, Germany/). HFFC cells were cultured in DMEM with 15% FCS and antibiotics (100 µg/mL streptomycin and 100 IU penicillin /Merck KGaA, Darmstadt, Germany/). The cells were cultured at 37 °C in an incubator maintaining high humidity and a gas mixture consisting of 5% CO2 and 95% atmospheric air.
2.8.3. In Vitro Cell Uptake Assay
Upon reaching 80% confluency, RAW264.7, A549, and HFFC cells were detached from the culture dish, and the concentration of viable cells in the resulting cell suspensions was determined. Next, a cell suspension with a concentration of 2 × 105 cells/mL was prepared and seeded onto a 96-well culture plate (TPP, Trasadingen, Switzerland) at a volume of 200 µL per well. After 24 h, RAW264.7 cells were stimulated with lipopolysaccharide (LPS) solution, which was added to the culture medium to a final concentration of 1 μg/mL. The cells were cultured in LPS-containing medium for 24 h. Subsequently, the cells were washed with DPBS and treated with fluorescein isothiocyanate (FITC)-labelled liposomes for 1 and 2 h. A549 and HFFC cells were seeded onto a 96-well culture plate (TPP, Trasadingen, Switzerland) at a concentration of 2 × 105 cells/mL, and after 24 h, the cells were treated with 50 µg/mL fluorescein isothiocyanate (FITC)-labelled liposomes for 1 and 2 h. At the end of the incubation period, all cell types were washed three times with DPBS, and liposome uptake by the cells was analyzed based on fluorescence signal detection (excitation 495 nm/emission 525 nm) using a SpectraMax i3x spectrophotometer (Molecular Devices, San Jose, CA, USA).
To determine the amount of fluorescent dye released from the liposomes during cell culture, the culture medium was collected after incubating the cells with FITC-labeled liposomes for 1 and 2 h. The collected medium was then centrifuged at 13,400 rpm for 1 h to pellet intact liposomes and cellular debris, and the resulting supernatant was analysed. The concentration of FITC in the resulting supernatant was assessed using a SpectraMax i3x spectrophotometer (Molecular Devices, San Jose, CA, USA) and a reference FITC standard (FITC in two-fold serial dilution in cell culture medium in the concentration range 0.00625–100 µg/mL). The results demonstrated that the concentration of fluorescent dye released from the liposomes following 1-h and 2-h incubation with LPS-stimulated RAW264.7 cells ranged from 0.010 to 0.035 µg/mL.
For analysis by fluorescence microscopy, the method described by Wang et al. [
28] was used with some modifications. RAW264.7 cells were seeded onto sterile slides at a concentration of 2 × 10
5 cells/mL, incubated for 24 h, and then stimulated with 1 μg/mL LPS for 24 h. Subsequently, the cells were washed with DPBS and treated with FITC-loaded liposomes for 2 h. Afterward, the cells were washed three times with DPBS and fixed with a 4% paraformaldehyde solution for 20 min at room temperature. After fixation, the cells were washed twice with DPBS and incubated in the dark with a 0.75 µg/mL solution of DAPI for 10 min at room temperature. The cells were then washed again with DPBS and observed using a Leica DM1000 LED epifluorescence microscope equipped with an I3 filter Leica Microsystems (Wetzlar, Germany) and a camera (Leica DM 2000 LED, Leica Microsystems, Wetzlar, Germany), using Leica Application Suite (LAS X5.0.2) software to document and analyze the images obtained.
2.8.4. Cell Viability Evaluations
To assess the viability of cells treated for 1 and 2 h with FITC-labelled liposomes, MTT assays were performed. A549 and HFFC cells were seeded and treated with liposomes as described in the previous subsection. RAW264.7 cells were seeded, stimulated with LPS, and treated with liposomes as described in the previous subsection. At the end of the 1- and 2-h incubation periods, the cells were washed three times with DPBS and incubated at 37 °C in cell culture medium containing 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,4-diphenyltetrazolium bromide (MTT) solution (Merck KGaA, Germany) for 2 h. During this incubation period, the yellow tetrazolium salt MTT is reduced by viable cells in the culture to purple formazan. Then, the culture medium was removed, and the formazan accumulated in cells was dissolved using 100 µL/well of DMSO. The culture plates were incubated for 15 min at room temperature on a shaker. After that, absorbance at 570 nm was measured using a Synergy-2 reader (BioTek, USA). The cytotoxic agent mitomycin C served as a positive control for all cell viability tests. All samples were analysed in triplicate. Results were expressed as the percentage of cell viability, calculated relative to the absorbance values of untreated control cells cultured for the same duration under standard growth conditions.
2.9. Statistical Analysis
Statistical analysis of the factorial design, as well as the Taguchi design, was performed using Minitab® Statistical Software version 21.1 (Minitab LLC, State College, PA, USA; 2023). For the polyelectrolyte titration, a one-way analysis of variance (ANOVA) was performed on the ζ-potential data for all polysaccharide-to-liposome ratios separately for iota-carrageenan and fucoidan, followed by Tukey’s honestly significant difference (HSD) post hoc test for pairwise comparisons. Comparison of the in vitro release profiles of the different formulations was performed using the model-independent similarity factor (f2), with f2 < 50 considered indicative of a statistically significant difference between profiles. For in vitro cell uptake assays analyses StatView software (version 5.0) (SAS Institute, Cary, NC, USA) was used to apply analysis of variance (ANOVA). Statistically significant differences between the samples were determined using Fisher’s PLSD test. Lower than 0.05 p-values were considered statistically significant. Unless otherwise stated, all experiments were conducted as three independent biological replicates, and the results are presented as the mean ± standard deviation (SD).
4. Conclusions
In the present work, xanthohumol-loaded cationic liposomes were successfully developed, surface-modified with the marine polysaccharides, iota-carrageenan and fucoidan, and stabilized by ionotropic cross-linking with Ca2+ ions. The 23 + 1 full factorial design demonstrated that the lipid concentration and the DPPC: DOTAP: cholesterol ratio were the dominant determinants of vesicle size, ζ-potential, and xanthohumol entrapment efficiency, with all three response models displaying high statistical reliability (R2 > 89%). Polyelectrolyte titration identified saturation of the liposomal surface at a 5:1 carrageenan-to-liposome ratio and at a 1:3 fucoidan-to-liposome ratio, while subsequent Taguchi L9 optimization revealed clearly distinct behaviours of the two polysaccharides during cross-linking: the iota-carrageenan shell was governed by a balanced contribution of polysaccharide concentration, CaCl2 concentration, and incubation time, consistent with cooperative, helix-templated Ca2+ coordination, whereas fucoidan was overwhelmingly dominated by CaCl2 concentration, in agreement with non-specific electrostatic crosslinking of its branched, sulfate-rich backbone.
The two cross-linked coatings translated these structural differences into pronounced differences in functional performance. Compared with the burst-type release of uncoated liposomes (≈55% within the 1st hour), the fucoidan coating reduced the early release of xanthohumol while still allowing near-complete release over 48 h, whereas the iota-carrageenan coating produced a markedly slower, sustained release (≈55% at 48 h) that was best described by Korsmeyer-Peppas, indicating a robust hydrogel-like diffusion barrier. In vitro uptake studies in RAW264.7 macrophages further demonstrated that, at a concentration of 50 µg/mL, both coatings substantially suppressed phagocytic internalization at 1 h, but only the iota-carrageenan shell sustained this protective effect at 2 h, while fucoidan-coated vesicles reverted to uptake levels indistinguishable from uncoated controls—possibly reflecting scavenger-receptor-mediated recognition of the highly sulfated fucoidan surface. The reduced uptake observed in non-phagocytic HFFC fibroblasts and the absence of significant differences in A549 epithelial cells confirmed that the protective effect of the coatings scales with the active phagocytic capacity of the target cell rather than reflecting a non-specific physicochemical barrier.
Overall, these results show that cross-linked iota-carrageenan coating presents an effective surface-engineering strategy for xanthohumol-loaded liposomes, simultaneously providing controlled and prolonged drug release and stable, time-independent evasion of macrophage uptake—features consistent with genuine “stealth-like” behaviour. Fucoidan coating, although less robust as long-term phagocytic shield, may still be of interest for applications in which a moderated burst effect combined with eventual macrophage targeting is desirable. It should be acknowledged that the hydrodynamic diameter of the optimal iota-carrageenan model (≈331 nm) lies above the size range most commonly associated with efficient passive, EPR-mediated tumour accumulation; however, passive extravasation is only one of several routes by which nanocarriers may reach tumour tissue, and the macrophage-evasion and controlled-release properties demonstrated here are expected to benefit systemic delivery independently of any single targeting mechanism. The platform described here therefore offers a versatile and tuneable basis for the further development of polysaccharide-coated liposomal carriers for the systemic or targeted delivery of fragile lipophilic actives such as xanthohumol and warrants further evaluation in pharmacokinetic and efficacy studies in vivo.